Un tratament experimental pentru hepatita B ar putea opri virusul în celulele ficatului. A intrat în testare la oameni

A new experimental therapy for hepatitis B, CRMA-1001, aims to permanently disable the virus in liver cells. This treatment utilizes a modified CRISPR technology that attaches chemical tags to the viral DNA, preventing gene activity and new virus production. Initial tests on human liver cells and animals showed significant reductions in viral markers, with some mice showing no detectable virus after treatment. The therapy is now in early human trials focusing on safety and efficacy, with the first participant treated in January 2026. Researchers caution that while results are promising, further studies are needed to confirm effectiveness in humans and potential for functional cure.